209 results
6-K
EX-99.1
GLPG
Galapagos NV
6 Nov 20
Current report (foreign)
10:06am
Medical Officer of Galapagos said: “Galapagos is very excited to gain access to OATD-01 and OncoArendi’s innovative pipeline of novel chitinase … is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information
6-K
EX-99.1
GLPG
Galapagos NV
27 Jan 22
Galapagos appoints Paul Stoffels as Chief Executive Officer
12:00am
focus on bringing innovative medicines to patients
Outstanding track record of accelerated product development in biotech and pharma through insightful … an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles
6-K
EX-99.1
GLPG
Galapagos NV
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients … Oncology at Galapagos. “These results demonstrate the potential of our innovative development and manufacturing approach in CAR-T cell therapy to transform
6-K
EX-99.1
GLPG
Galapagos NV
27 Oct 20
Current report (foreign)
12:13pm
) and potential broad applicability of salt-inducible kinase (SIK) inhibitors in inflammation
Innovative chemistry generated multiple series of SIK compounds … innovative chemistry to address a number of selectivity profiles, and we now also show promising preclinical activity in fibrotic models, further
6-K
EX-99.1
GLPG
Galapagos NV
9 Apr 21
Extension of lock-up period in Gilead-Galapagos collaboration agreement
6:00am
research and development collaboration, giving Gilead access to Galapagos’ innovative portfolio of compounds and drug discovery platform. As part … -year global transformative research and development collaboration. Through this agreement, Gilead gained access to an innovative portfolio
6-K
EX-99.1
swtm1vs11lg 2l7zaxa
7 Feb 19
Evotec and Galapagos enter into collaboration in the field of fibrosis
8:09am
6-K
EX-99.1
3rxzv2vjb4ymcvx3isbz
23 Jun 22
Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies
11:21am
6-K
EX-99.1
rih2c03582kgnh
19 Jan 22
Jyseleca®▼ (Filgotinib) Licensed for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis In Great Britain
11:37am
6-K
EX-99.1
jvom9izngz rywq9mgd
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
EX-99.1
7j6sx6uikp5 fdc
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.1
uz1k4
24 Jan 20
Galapagos appoints Michele Manto as Chief Commercial Officer
8:52am
6-K
EX-99.1
6gosyxpogcipxs6 fd
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
6-K
EX-99.1
u70mus740 rgg
8 Jun 20
Current report (foreign)
6:00am
6-K
EX-99.1
uoqde5a q4n
2 Jul 19
Gilead Announces Intent to Submit New Drug Application for Filgotinib to U.s. Food and Drug Administration This Year
6:08am
6-K
EX-99.1
4nuv50
13 Aug 20
Current report (foreign)
9:42am
6-K
EX-99.1
ftc9y 9hh0dmnot80
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
6-K
EX-99.1
m1fcvxt88u7gcty
10 Feb 21
Current report (foreign)
11:31am
6-K
EX-99.1
jrf93j hgjshud2fxq42
24 Apr 19
Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
6:01am
6-K
EX-99.1
ryrix ks2gf51sfod
15 Jul 19
Gilead and Galapagos Enter into Transformative Research and Development Collaboration
11:59am
6-K
EX-99.1
ftlph7odj45bz9j
19 Aug 20
Current report (foreign)
6:00am